---
title: "A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697)."
description: "Dolutegravir (DTG, GSK1349572) is an integrase inhibitor that is currently in Phase 3 clinical development for the treatment of human immunodeficiency viru"
url: "https://www.clareohealth.com/clinical-trials/NCT01563328"
---

Dolutegravir (DTG, GSK1349572) is an integrase inhibitor that is currently in Phase 3 clinical development for the treatment of human immunodeficiency virus (HIV) infection. Co-infection with Hepatitis C (HCV) is common in HIV-infected subjects therefore it is expected that DTG will be coadministered with treatments for HCV. Boceprevir (BCV) and Telaprevir (TVR) are protease inhibitors for the treatment of HCV that were recently approved by the Food and Drug Administration/European Medicines Agency (FDA/EMA) and have rapidly been adopted to "standard of care" in combination with pegylated interferon and ribavarin. This is a single-center, open-label, two-cohort, two-period, one-way, study in healthy adult subjects. A total of approximately 32 subjects will be enrolled, in order to obtain 24 evaluable subjects (12 per cohort). In the first treatment period, all subjects will receive DTG 50 mg once daily for 5 days (treatment A). In period 2, subjects will receive DTG 50 mg once daily plus either BCV 800 mg q8h (treatment B) for 10 days or TVR 750 mg q8h (treatment C) for 10 days. There will be no washout between treatments. Safety evaluations and serial PK samples will be collected during each treatment period. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. This study will be conducted at one center in the US, with healthy adult male and female subjects.

## Key Facts

**ID:** NCT01563328
**Status:** COMPLETED
**Phase:** PHASE1
**Type:** INTERVENTIONAL
**Enrollment:** 32
**Sponsor:** ViiV Healthcare

## About This Study

This clinical trial is testing how two medications, Boceprevir and Telaprevir, affect the levels of Dolutegravir in the body. It is for healthy adults aged 18 to 65 years, and aims to understand how these drugs interact when taken together.

## Conditions

- Infection, Human Immunodeficiency Virus

## Interventions

**DRUG: DTG**
50 mg q24h

**DRUG: BCV**
800 mg q8h

**DRUG: TVR**
750 mg q8h

## Eligibility

Inclusion Criteria: * ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).

## Who Can Participate

**Minimum age:** 18

**Maximum age:** 65

**Sex:** ALL

**Accepts healthy volunteers:** Yes

## Study Locations

- GSK Investigational Site, Austin, Texas, United States

## Contact Information

## Important Dates

**Study start:** March 1, 2012

**Completion date:** May 1, 2012

**Last updated:** March 28, 2017

## Collaborators

- Shionogi
- GlaxoSmithKline

## Consider Discussing with Your Care Team

### Worth Discussing If

- You are interested in how different HIV treatments work together.
- You are a healthy adult between 18 and 65 years old.
- You want to contribute to research on HIV medications.

### Questions to Ask

- What are the potential side effects of the medications being tested?
- How will my health be monitored during the study?
- What should I do if I experience any adverse effects?
- How will this study help improve treatments for HIV?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01563328)
